BioCentury | Jul 15, 2017
Company News

Management tracks

...as chief regulatory officer. She had been a regulatory consultant since serving as COO of Cardeas Pharma Corp....
BioCentury | May 15, 2017
Financial News

Genoa's series A brings in $62M

...CEO. He replaced founder Mark Surber, who will be Genoa's CSO. Montgomery was CEO at Cardeas Pharma Corp....
BioCentury | Jan 20, 2014
Clinical News

Amikacin Fosfomycin Inhalation System: Phase II started

...receive Priority Review and Fast Track designation under the Generating Antibiotic Incentives Now (GAIN) program. Cardeas Pharma Corp....
BioCentury | Jan 20, 2014
Clinical News

Amikacin Fosfomycin Inhalation System regulatory update

...mechanically ventilated patients. The product is an inhalation solution of the antibiotics amikacin and fosfomycin. Cardeas Pharma Corp....
BioCentury | May 27, 2013
Clinical News

Amikacin/fosfomycin inhalation solution: Phase Ib data

...to start Phase II testing of the product, but could not be reached for details. Cardeas Pharma Corp....
BioCentury | May 27, 2013
Financial News

Cardeas Pharma completes venture financing

Cardeas Pharma Corp. , Seattle, Wash. Business: Infectious Date completed: 5/22/13 Type: Venture financing Raised: $34 million Investors: H.I.G. Capital; Novo A/S; Avalon Ventures; Devon Park Bioventures; WRF Capital; Delphi Ventures WIR Staff Infectious...
BioCentury | May 27, 2013
Company News

Cardeas Pharma board of directors update

Cardeas Pharma Corp. , Seattle, Wash. Business: Infectious Appointed: Aaron Davidson, managing director of H.I.G. BioVentures WIR Staff Infectious...
BioCentury | May 24, 2013
Financial News

Cardeas raises $34M in series B

...Infectious disease company Cardeas Pharma Corp. (Seattle, Wash.) raised $34 million in a series B round led by...
BioCentury | Sep 10, 2012
Finance

Avalon reloads

...sciences. Previous life science investments include CNS disease company Afraxis Inc. , infectious disease play Cardeas Pharma Corp....
Items per page:
1 - 9 of 9
BioCentury | Jul 15, 2017
Company News

Management tracks

...as chief regulatory officer. She had been a regulatory consultant since serving as COO of Cardeas Pharma Corp....
BioCentury | May 15, 2017
Financial News

Genoa's series A brings in $62M

...CEO. He replaced founder Mark Surber, who will be Genoa's CSO. Montgomery was CEO at Cardeas Pharma Corp....
BioCentury | Jan 20, 2014
Clinical News

Amikacin Fosfomycin Inhalation System: Phase II started

...receive Priority Review and Fast Track designation under the Generating Antibiotic Incentives Now (GAIN) program. Cardeas Pharma Corp....
BioCentury | Jan 20, 2014
Clinical News

Amikacin Fosfomycin Inhalation System regulatory update

...mechanically ventilated patients. The product is an inhalation solution of the antibiotics amikacin and fosfomycin. Cardeas Pharma Corp....
BioCentury | May 27, 2013
Clinical News

Amikacin/fosfomycin inhalation solution: Phase Ib data

...to start Phase II testing of the product, but could not be reached for details. Cardeas Pharma Corp....
BioCentury | May 27, 2013
Financial News

Cardeas Pharma completes venture financing

Cardeas Pharma Corp. , Seattle, Wash. Business: Infectious Date completed: 5/22/13 Type: Venture financing Raised: $34 million Investors: H.I.G. Capital; Novo A/S; Avalon Ventures; Devon Park Bioventures; WRF Capital; Delphi Ventures WIR Staff Infectious...
BioCentury | May 27, 2013
Company News

Cardeas Pharma board of directors update

Cardeas Pharma Corp. , Seattle, Wash. Business: Infectious Appointed: Aaron Davidson, managing director of H.I.G. BioVentures WIR Staff Infectious...
BioCentury | May 24, 2013
Financial News

Cardeas raises $34M in series B

...Infectious disease company Cardeas Pharma Corp. (Seattle, Wash.) raised $34 million in a series B round led by...
BioCentury | Sep 10, 2012
Finance

Avalon reloads

...sciences. Previous life science investments include CNS disease company Afraxis Inc. , infectious disease play Cardeas Pharma Corp....
Items per page:
1 - 9 of 9